Given the current scenario of the fashion and lifestyle category, adapting to the ‘new normal’ is the need of the hour. Being a market leader in innovation and excellence, the Donear Group, using Neotech® technology, has conceived products that are high quality, utilitarian and have a shield against bacteria and viruses alike.
The group has been a pioneer in introducing a lot of innovative products in the market in the past as well with products such as Streeza, Ice Touch and Uncrushables (for wrinkle resistance) amongst others, which are continuing to fare extremely well. With this step, the Group makes a bold advance towards perfecting an antiviral technology which will go a long way to strengthen their presence in the poly viscose and worsteds categories.
Leveraging NEO TECH® techniques, the Donear Group has developed specially designed anti-viral and anti-bacterial fabrics that inhibits growth and retention of micro-organisms, making them safe and hygienic. NEO TECH® anti-viral fabrics have been certified safe to wear/ use for any kind of garment-suits/ jackets/ trousers. These fabrics retain their properties up to even 50 washes, and are suited for everyday wear.
Known for their pioneering efforts, NEO TECH® has partnered with HeiQ, a Swiss company,to power up its suiting & worsted fabrics with an intelligent textile technology - HeiQ Viroblock NPJ03.
HeiQ Viroblock NPJ03 is among the first textile technologies in the world to be proven & certified effective against SARS-CoV-2. Tests conducted by them in Melbourne, showed that treated fabric achieved 99.99 per cent reduction of the virus.
The research project involved a disinfection test protocol simulating real-life interaction of small aerosol droplets contaminating clothing with a known concentration of SARS-CoV-2 virus. The virus was contacted with the sample fabric for a few minutes followed by measurement of remaining infectious SARS-CoV-2 viruses.
When the fabric sample was treated with HeiQ Viroblock NPJ03, no infective viruses left after a few minutes and the result indicated a SARS-CoV-2 virus reduction of 99.99% relative to the inoculum control.